Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Código da empresaTNYA
Nome da EmpresaTenaya Therapeutics Inc
Data de listagemJul 30, 2021
CEOMr. Faraz Ali
Número de funcionários97
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 30
Endereço171 Oyster Point Blvd., Suite 500
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone14158652066
Sitehttps://www.tenayatherapeutics.com/
Código da empresaTNYA
Data de listagemJul 30, 2021
CEOMr. Faraz Ali
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados